Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Andrew Davies: EHA 2020 lymphoma highlights

Andrew Davies • 19 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma AUTO3 CAR-T Inotuzumab ozogamicin Loncastuximab tesirine Rituximab
ALEXANDER IELSG 37 INCA

Andrew Davies, BSc, BM, MRCP, PhD, of the University of Southampton, Southampton, UK, explores exciting updates in lymphoma presented at EHA 2020. Dr Davies discusses the NCRI INCA study evaluating inotuzumab ozogamicin plus rituximab for diffuse large B-cell lymphoma (DLBCL) patients ineligible for R-CHOP chemotherapy, CAR T-cell therapies such as AUTO3 evaluated in the ALEXANDER study (NCT03287817) and recent trials investigating loncastuximab tesirine, an antibody-drug conjugate, in relapsed/refractory DLBCL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals